Contraception
Volume 80, Issue 6 , Pages 519-526 , December 2009

Safety of the etonogestrel-releasing implant during the immediate postpartum period: a pilot study

  • Milena Bastos Brito

      Affiliations

    • Department of Obstetrics and Gynecology, University of São Paulo, Ribeirão Preto, School of Medicine, Ribeirão Preto, SP, 14049-900, Brazil
    • ,
  • Rui Alberto Ferriani

      Affiliations

    • Department of Obstetrics and Gynecology, University of São Paulo, Ribeirão Preto, School of Medicine, Ribeirão Preto, SP, 14049-900, Brazil
    • National Institute of Hormones and Women's Health, Ribeirão Preto, SP, 14049-900, Brazil
    • ,
  • Silvana Maria Quintana

      Affiliations

    • Department of Obstetrics and Gynecology, University of São Paulo, Ribeirão Preto, School of Medicine, Ribeirão Preto, SP, 14049-900, Brazil
    • ,
  • Marta Edna Holanda Diogenes Yazlle

      Affiliations

    • Department of Obstetrics and Gynecology, University of São Paulo, Ribeirão Preto, School of Medicine, Ribeirão Preto, SP, 14049-900, Brazil
    • ,
  • Marcos Felipe Silva de Sá

      Affiliations

    • Department of Obstetrics and Gynecology, University of São Paulo, Ribeirão Preto, School of Medicine, Ribeirão Preto, SP, 14049-900, Brazil
    • National Institute of Hormones and Women's Health, Ribeirão Preto, SP, 14049-900, Brazil
    • ,
  • Carolina Sales Vieira

      Affiliations

    • Department of Obstetrics and Gynecology, University of São Paulo, Ribeirão Preto, School of Medicine, Ribeirão Preto, SP, 14049-900, Brazil
    • National Institute of Hormones and Women's Health, Ribeirão Preto, SP, 14049-900, Brazil
    • Corresponding Author InformationCorresponding author. Carolina Sales Vieira, Avenida Bandeirantes, 3900, Campus Universitário, Monte Alegre, Ribeirão Preto, SP, CEP-14049-900, Brasil. Tel.: +55 16 36022804; fax: +55 16 36330946.

Received 12 February 2009 ,Revised 17 April 2009 ,Accepted 21 May 2009.

References 

  1. United Nations Population Fund (UNFPA) . Safe motherhood: reducing risks by offering contraceptive services, 2008. Accessed 15 January 2009. Available on line in: http://www.unfpa.org/mothers/contraceptive.htm#unwanted
  2. Conde-Agudelo A, Belizan JM. Maternal morbidity and mortality associated with interpregnancy interval: cross sectional study. BMJ. 2000;321:1255–1259
  3. Rousso D, Panidis D, Gkoutzioulis F, Kourtis A, Mavromatidis G, Kalahanis I. Effect of the interval between pregnancies on the health of mother and child. Eur J Obstet Gynecol Reprod Biol. 2002;105:4–6
  4. Rutstein SO. Effects of preceding birth intervals on neonatal, infant and under-five years mortality and nutritional status in developing countries: evidence from the demographic and health surveys. Int J Gynaecol Obstet. 2005;9:S7–S24
  5. World Health Organization . Medical eligibility criteria for contraceptive use. 3rd ed.. Geneva: World Health Organization; 2004;
  6. Committee on Health Care for Underserved Women . American College of Obstetricians and Gynecologists. ACOG Committee Opinion No. 361: Breastfeeding: maternal and infant aspects. Obstet Gynecol. 2007;9(2 Pt 1):479–480
  7. McCann MF, Moggia AV, Higgins JE, Potts M, Becker C. The effects of a progestin-only oral contraceptive (levonorgestrel 0.03 mg) on breast-feeding. Contraception. 1989;40:635–648
  8. Moggia AV, Harris GS, Dunson TR, et al. A comparative study of a progestin-only oral contraceptive versus non-hormonal methods in lactating women in Buenos Aires, Argentina. Contraception. 1991;44:31–43
  9. Halderman LD, Nelson AL. Impact of early postpartum administration of progestin-only hormonal contraceptives compared with nonhormonal contraceptives on short- term breast-feeding patterns. Am J Obstet Gynecol. 2002;186:1250–1256
  10. Karim M, Ammar R, el-Mahgoub S, el-Ganzoury B, Fikri F, Abdou I. Injected progestogen and lactation. Br Med J. 1971;1:200–203
  11. Darney P, Patel A, Rosen K, Shapiro LS, Kaunitz AM. Safety and efficacy of a single-rod etonogestrel implant (Implanon): results from 11 international clinical trials. Fertil Steril. 2009;91:1646–1653
  12. Reinprayoon D, Taneepanichskul S, Bunyavejchevin S, et al. Effects of the etonogestrel-releasing contraceptive implant (Implanon®) on parameters of breastfeeding compared with those of an intrauterine device. Contraception. 2000;62:239–246
  13. Taneepanichskul S, Reinprayoon D, Thaithumyanon P, Praisuwanna P, Tosukhowong P, Dieben T. Effects of the etonogestrel-releasing implant (Implanon®) and a nonmedicated intrauterine device on the growth of breast-fed infants. Contraception. 2006;73:368–371
  14. Labbok M, Cooney K, Coly S. 3rd ed.. Guidelines for breast-feeding and the lactational amenorrhea method. 58. Washington, DC: Institute for Reproductive Health; 1994;
  15. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499–502
  16. Truitt ST, Fraser AB, Grimes DA, Gallo MF, Schulz KF. Hormonal contraception during lactation. systematic review of randomized controlled trials. Contraception. 2003;68:233–238
  17. Campbell OM, Gray RH. Characteristics and determinants of postpartum ovarian function in women in the United States. Am J Obstet Gynecol. 1993;169:55–60
  18. Urbancsek J. An integrated analysis of nonmenstrual adverse events with Implanon. Contraception. 1998;58:109S–115S
  19. Brache V, Faundes A, Alvarez F, Cochon L. Nonmenstrual adverse events during use of implantable contraceptives for women: data from clinical trials. Contraception. 2002;65:63–74
  20. Phemister DA, Laurent S, Harrison FN. Use of Norplant contraceptive implants in the immediate postpartum period: safety and tolerance. Am J Obstet Gynecol. 1995;172:175–179
  21. Croxatto HB. Progestin implants. Steroids. 2000;65:681–685
  22. Affandi B. An integrated analysis of vaginal bleeding patterns in clinical trials of Implanon. Contraception. 1998;58:99S–107S
  23. Patel SB, Toddywalla VS, Betrabet SS, et al. At what “infant-age” can levonorgestrel contraceptives be recommended to nursing mothers?. Adv Contracept. 1994;10:249–255
  24. Suherman SK, Affandi B, Korver T. The effects of Implanon on lipid metabolism in comparison with Norplant. Contraception. 1999;60:281–287
  25. Innal MM, Yildirim Y, Ertopcu K, Avci ME, Ozelmas I, Tinar S. Effect of the subdermal contraceptive etonogestrel. Eur J Contracept Reprod Health Care. 2008;28:1–5
  26. Biswas A, Viegas OAC, Bennink HJTC, Korver T, Ratnam SS. Implanon® contraceptive implants: effects on carbohydrate metabolism. Contraception. 2001;63:137–141

PII: S0010-7824(09)00277-7

doi: 10.1016/j.contraception.2009.05.124

Contraception
Volume 80, Issue 6 , Pages 519-526 , December 2009

Article Tools

* Image Usage & Resolution